Alpha Tau Medical
Develops Alpha DaRT, a localized alpha-radiation therapy for solid tumors.
Something off on this page? Send us feedback.
Profile
Develops Alpha DaRT, a local alpha-radiation platform for solid tumors. The clinical-stage business depends on advancing that single technology through trials, regulation, and commercialization.
Alpha DaRT is a local alpha-radiation platform designed for solid tumors. Operations span technology and IP development, pre-clinical and clinical research, and preparation for commercialization. The core facility is in Jerusalem and most of the workforce is in Israel, while subsidiaries establish an operating presence in the United States, Japan, and Canada.
In Japan, Alpha DaRT has marketing approval for unresectable locally advanced or locally recurrent head-and-neck cancer. In the United States, the platform remains in development toward possible FDA approval; at the reporting date, no product had been approved for sale there. The business depends on clinical-trial enrollment, regulatory compliance, intellectual-property protection, and access to capital.
Company facts
Key statistics
Year to date +204% · Average volume (30d) 525.3K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 11, 2026 | H.C. Wainwright | Target | $15 | $16 | ||
| Jun 4, 2026 | Barclays | Reiterate | Overweight | $15 | $17 | |
| May 28, 2026 | Barclays | Target | $15 | |||
| May 19, 2026 | Piper Sandler | Reiterate | Neutral | $7 | $8 | |
| May 12, 2026 | H.C. Wainwright | Target | $12 | $15 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026Q2 FY26 | −$0.14 | −$0.50 | −254.9% | $144.5K | $100.0K | −30.8% | +4.93% |
| May 18, 2026Q1 FY26 | −$0.13 | −$0.26 | −100.0% | $49.8K | — | — | +6.48% |
| Mar 9, 2026Q4 FY25 | −$0.13 | −$0.14 | −7.7% | $63.0K | — | — | +1.94% |
| Nov 20, 2025Q3 FY25 | −$0.12 | −$0.14 | −16.7% | — | — | — | +10.09% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating income | −$9.3M | −$9.6M | −$10.7M | −$12.6M | −$13.3M | −$13.8M | |
| Net income | −$8.7M | −$10.1M | −$11.7M | −$12.1M | −$22.9M | −$45.8M | |
| Diluted EPS | −$0.12 | −$0.13 | −$0.14 | −$0.14 | −$0.26 | −$0.50 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $100.6M · Total debt $15.2M · Total assets $134.3M · Shareholders' equity $44.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 90.33M · Float 61.99M · 68.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Oramed Pharmaceuticals Inc. | 14.11M | 19.99% | 13D | May 1, 2025 |
| Michael Avruch · director | 1.57M | 1.74% | Form 4 | Mar 18, 2026 |
| Uzi Sofer · director, officer: Chief Executive Officer | 1.25M | 1.38% | Form 4 | Mar 18, 2026 |
| Hightower Advisors, LLC | 875.0K | 0.97% | 13F | May 5, 2026 |
| Aquamarine Financial (Cayman) Ltd | 721.5K | 0.80% | 13F | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 21, 2026 | Raphi Levy | officer: Chief Financial Officer | −2,871 | $15.00 |
| Aug 11, 2026 | Raphi Levy | officer: Chief Financial Officer | −17,730 | $14.00 |
| Jul 6, 2026 | Raphi Levy | officer: Chief Financial Officer | −2,270 | $14.00 |
| Jul 2, 2026 | Raphi Levy | officer: Chief Financial Officer | −17,873 | $13.00 |
| Jul 1, 2026 | Raphi Levy | officer: Chief Financial Officer | −2,127 | $13.02 |
Peers
- Accuray
Robotic radiosurgery and IMRT systems for cancer treatment
- Nanobiotix (ADR)
Intratumoral radioenhancement activated by radiation therapy
- Boston Scientific
Y-90 radioembolization for hepatocellular carcinoma
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Alpha Tau Medical | $14.85 | +1.23% | $1.32B | — | — | — | — |
| Accuray | $0.2600 | −5.56% | $32.6M | — | — | 0.1 | −20.9% |
| Nanobiotix (ADR) | $40.83 | −0.61% | $2.09B | — | — | 62.1 | — |
| Boston Scientific | $46.85 | +0.03% | $69.62B | 19.0 | 14.2 | 3.3 | +7.5% |
| Median | 19.0 | 14.2 | 3.3 | −6.7% |